Evidence map›Paper›PMID 39861957›Full record

Observational studyCancer medicine2025

Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study.

Geoffrey Liu, Shi Feng Nyaw, Tony S K Mok, Hubert Curcio, Alexis B Cortot, Tsz Yeung Kam, Renaud Descourt, Yin Kwan Chik, Parneet Cheema, James M Gwinnutt and 9 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05207423 (Patterns of Care and Clinical Outcomes of Patients With Advanced Non-small Cell Lung Cancer), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05207423 completednot on this map

Patterns of Care and Clinical Outcomes of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

TypeobservationalSponsorTakedaRan2022 to 2023Enrolled179ConditionsNon-small Cell Lung Cancer (NSCLC)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Geoffrey LiuDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Shi Feng NyawDepartment of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China.
Tony S K MokDepartment of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.
Hubert CurcioOncology Department, Centre Francois Baclesse, Caen, France.
Alexis B CortotCentre Hospitalier Universitaire de Lille, CNRS, INSERM, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.
Tsz Yeung KamDepartment of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital Main Block, Hong Kong, China.
Renaud DescourtOncology Department, Hopital Morvan, CHU Brest, Brest, France.
Yin Kwan ChikDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China.
Parneet CheemaOncology, William Osler Health System, University of Toronto, Brampton, Ontario, Canada.
James M GwinnuttEpidemiology and Database Studies, IQVIA, Reading, England, UK.
Eric N ChurchillGlobal Medical Affairs Oncology, Takeda Pharmaceuticals U.S.A., Inc., Lexington, Massachusetts, USA.
Justin NybornGlobal Medical Affairs Oncology, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Eileen CurranGlobal Evidence and Outcome Research, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Alexandra SavellGlobal Medical Affairs Oncology, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Yu YinObservational Research Analytics, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Katie ChongClinical Data Management, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Yuka Tanaka-ChambersStatistical and Quantitative Sciences, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Julian KretzMedical Affairs Oncology - EUCan, Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Jacques CadranelPulmonology and Thoracic Oncology Department, APHP Hôpital Tenon and Sorbonne Université, Paris, France.ORCID https://orcid.org/0000-0003-2446-2923

Funding

Takeda Development Center Americas, Inc.
6 · The paper itself

Abstract

backgroundReal-world data regarding patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations receiving mobocertinib are limited. This study describes these patients' characteristics and outcomes.

methodsA chart review was conducted across three countries (Canada, France, and Hong Kong), abstracting data from eligible patients (NCT05207423). The inclusion criteria were: ≥ 18 years old; diagnosis of stage IIIB-IV NSCLC with EGFR ex20ins between January 1, 2017 and November 30, 2021; received mobocertinib. Data on demographics, clinical parameters, treatment patterns, mobocertinib exposure, real-world outcomes, and adverse events (AEs) were collected. Results are also reported by Asian/Non-Asian races.

resultsOverall, 105 patients were enrolled (median [IQR] age at initial diagnosis: 64.0 years [56, 71]; women: 62.9%). The most common first-line of therapy (LoT) was chemotherapy; the most common second LoT was EGFR tyrosine kinase inhibitors. Most patients received mobocertinib during LoT two and three (74.3%); the maximum dose was 160 mg/day for 67.6% of the cohort (mean [SD] daily dose: 130.6 mg [36.68]). The median real-world progression-free survival (PFS) on mobocertinib was 4.76 months (95% CI: 3.98, 6.21). The overall response rate and disease control rate were 20.0% and 48.6%, respectively (median duration of response: 8.34 months [95% CI: 3.61, 9.49]). The median overall survival (OS) was 26.28 months (95% CI: 20.21, 36.44). Asian patients had numerically superior PFS and OS compared with non-Asian patients. Regarding safety analysis, 73 patients (69.5%) experienced any AE. The most common AE was diarrhea (any grade) (52 patients; 49.5%).

conclusionsThese data illustrate the real-world effectiveness of mobocertinib.

Indexed as

AcrylamidesCarcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsAgedAniline CompoundsErbB ReceptorsExonsFemaleHong KongHumansIndolesMaleMiddle AgedMutagenesis, InsertionalMutationAcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsHM781-36BIndolesmobocertinibProtein Kinase InhibitorsPyrimidinesQuinazolinesEGFR exon 20 insertionmobocertinibnon‐small cell lung cancerreal‐world outcomes

Identifiers

PMID39861957
PMCPMC11761427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.